(Q44991118)

English

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 December 2017

Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome (English)

1 reference

Europe PubMed Central

8 December 2017

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Geoffrey J. Lindeman

3

1 reference

Europe PubMed Central

8 December 2017

author name string

Ross R Jennens

1

1 reference

Europe PubMed Central

8 December 2017

Mark A Rosenthal

2

1 reference

Europe PubMed Central

8 December 2017

Michael Michael

4

1 reference

Europe PubMed Central

8 December 2017

publication date

1 May 2004

1 reference

Europe PubMed Central

8 December 2017

Urologic Oncology

1 reference

Europe PubMed Central

8 December 2017

22

1 reference

Europe PubMed Central

8 December 2017

193-196

1 reference

Europe PubMed Central

8 December 2017

3

1 reference

Europe PubMed Central

8 December 2017

Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Von Hippel-Lindau Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

von Hippel-Lindau disease: genetic, clinical, and imaging features

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Novel therapies for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Venous thromboembolism and occult malignancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2004.01.011

7 January 2021

Identifiers

10.1016/J.UROLONC.2004.01.011

1 reference

Europe PubMed Central

8 December 2017

1 reference

Europe PubMed Central

8 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44991118&oldid=2060689895"